Stammdaten
Vor Biopharma, Inc. ist ein Unternehmen in der klinischen Phase, das gentechnisch veränderte hämatopoetische Stammzell- (eHSC) Therapien für Krebspatienten entwickelt. Das Unternehmen entwickelt VOR33, einen eHSC-Produktkandidaten, der sich in Phase 1/2 zur Behandlung von akuter myeloischer Leukämie (AML) und anderen hämatologischen Malignomen befindet. VOR33 eHSCs des Unternehmens fehlt CD33, ein Protein, das von AML-Blutkrebs-Zellen exprimiert wird. Die gezielten eHSC-Therapien des Unternehmens, wie CAR-Ts, bispezifische Antikörper und Antikörper-Wirkstoff-Konjugate, bieten eine Behandlung für Blutkrebs. Vor Biopharma, Inc. hat eine Kooperationsvereinbarung mit Akron BioProducts zur Entwicklung und Herstellung von cGMP-Nukleasen. Das Unternehmen wurde 2015 gegründet und hat seinen Sitz in Cambridge, Massachusetts. KI
Unternehmen & Branche
| Name | Vor Biopharma Inc. |
|---|---|
| Ticker | VOR |
| CIK | 0001817229 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 929033108 |
|---|---|
| ISIN | US9290331084 |
| Typ | Common Stock |
| Marktkapitalisierung | 745,8 Mio. USD |
| Beta | -0,63 |
Sitz & Kontakt
| Geschäftsadresse | 500 BOYLSTON STREET SUITE 1350, 02116 BOSTON, MA |
|---|---|
| Telefon | 617-655-6580 |
| EIN (IRS) | 81-1591163 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Emerging growth company |
Bewertung
| FCF-Rendite | -19,3 % vs. -0,8 % (2021) ▼ |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 39,95 | 35,02 | 20,27 | 1,43 | – | – | |
| FCF-Rendite | -0,8 % | -1,1 % | -3,3 % | -72,1 % | -28,4 % | -20,2 % | |
| Qualität & Bilanz | |||||||
| ROIC | -29,4 % | -31,8 % | -63,2 % | -91,0 % | – | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
VOR
Vor Biopharma Inc.
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
40,3
32 neu, 24 erhöht, 347,6M $ netto
Aktivist
57,5
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 16.26 | +19.6 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 15.75 | +23.4 % vs SMA200 | |
| SMA-Cross | Bullisch | 10 % | GOLDEN | vor 3 Tagen @ 19.51 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 18.38 | EMA50: 17.04 | |
| MACD-Histogramm | Bärisch | 10 % | -0.067 | Bearisch | |
| RSI(14) | Neutral | 10 % | 58.4 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 64.7 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 30.1 | +DI: 26.9 / −DI: 13.2 | |
| Z-Score(60) | Neutral | 5 % | 1.47 | In Range | |
| 52W-Position | Neutral | 5 % | 30.1 % | Hoch 48.72 / Tief 6.86 | |
| Bollinger(20,2σ) | Neutral | 5 % | 61.5 % | Upper 20.89 / Mid 19.01 / Lower 17.12 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.0849 | R²=0.43 / annualisiert +132.3 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Open Market Sale | -213 | 19,75 | -4.206,75 | -0,3% | |
| 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -165.150 | 15,77 | -2.604.415,50 | -202,1% | |
| 2026-04-20 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -171.963 | 15,77 | -2.711.856,51 | -210,5% | |
| 2026-04-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -458.411 | 16,28 | -7.462.931,08 | -579,2% | |
| 2026-04-15 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -53.644 | 16,01 | -858.840,44 | -66,7% | |
| 2026-04-14 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -153.735 | 15,97 | -2.455.147,95 | -190,5% | |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -530.610 | 16,15 | -8.569.351,50 | -665,0% | |
| 2026-04-10 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -828 | 15,75 | -13.041,00 | -1,0% | |
| 2026-04-09 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -135.201 | 16,59 | -2.242.984,59 | -174,1% | |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -353.242 | 16,32 | -5.764.909,44 | -447,4% | |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -130.862 | 16,91 | -2.212.876,42 | -171,7% | |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -44.728 | 17,31 | -774.241,68 | -60,1% | |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -537.754 | 16,51 | -8.878.318,54 | -689,0% | |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -6.775 | 18,50 | -125.337,50 | -9,7% | |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -258.475 | 18,23 | -4.711.999,25 | -365,7% | |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -1.525 | 19,06 | -29.066,50 | -2,3% | |
| 2025-10-30 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -24.579 | 25,12 | -617.424,48 | -47,9% | |
| 2025-10-29 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -251.518 | 25,22 | -6.343.283,96 | -492,3% | |
| 2025-10-28 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -87.828 | 27,10 | -2.380.138,80 | -184,7% | |
| 2025-10-28 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -36.483 | 28,18 | -1.028.090,94 | -79,8% | |
| 2025-10-27 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -90.941 | 28,12 | -2.557.260,92 | -198,5% | |
| 2025-10-24 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -53.345 | 28,01 | -1.494.193,45 | -116,0% | |
| 2025-10-23 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -76.880 | 28,01 | -2.153.408,80 | -167,1% | |
| 2025-10-21 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -25.027 | 28,11 | -703.508,97 | -54,6% | |
| 2025-10-21 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -200 | 30,08 | -6.015,00 | -0,5% | |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -70.366 | 29,63 | -2.084.944,58 | -161,8% | |
| 2025-10-20 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -11.616 | 30,05 | -349.101,46 | -27,1% | |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -13.817 | 29,63 | -409.397,71 | -31,8% | |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -6.553 | 30,12 | -197.376,36 | -15,3% | |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -1.287 | 30,12 | -38.764,44 | -3,0% | |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -6.040 | 30,28 | -182.891,20 | -14,2% | |
| 2025-10-17 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -24.689 | 30,22 | -746.118,86 | -57,9% | |
| 2025-10-17 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -1.028 | 31,00 | -31.868,00 | -2,5% | |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -174.594 | 29,12 | -5.084.177,28 | -394,6% | |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -34.284 | 29,12 | -998.350,08 | -77,5% | |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -30.758 | 30,28 | -931.352,24 | -72,3% | |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -12.691 | 31,00 | -393.421,00 | -30,5% | |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -2.492 | 31,00 | -77.252,00 | -6,0% | |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -20 | 31,35 | -627,00 | 0,0% | |
| 2025-10-16 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -2.021 | 30,45 | -61.549,15 | -4,8% | |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -4 | 31,35 | -125,40 | 0,0% | |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -3.108 | 30,36 | -94.358,88 | -7,3% | |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -15.826 | 30,36 | -480.477,36 | -37,3% | |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -21.804 | 29,32 | -639.293,28 | -49,6% | |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -111.041 | 29,32 | -3.255.722,12 | -252,7% | |
| 2025-10-15 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -7.894 | 32,77 | -258.712,43 | -20,1% | |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -42.699 | 30,55 | -1.304.454,45 | -101,2% | |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -8.384 | 30,55 | -256.131,20 | -19,9% | |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -234 | 31,17 | -7.293,78 | -0,6% | |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Sale | -46 | 31,17 | -1.433,82 | -0,1% | |
| 2025-10-15 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -48.910 | 32,05 | -1.567.364,97 | -121,6% | |
| 2025-10-15 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -14.851 | 31,05 | -461.117,61 | -35,8% | |
| 2025-10-14 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -33.668 | 30,32 | -1.020.786,83 | -79,2% | |
| 2025-10-13 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -2.334 | 33,09 | -77.225,76 | -6,0% | |
| 2025-10-13 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -19.672 | 32,36 | -636.560,35 | -49,4% | |
| 2025-10-10 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -40.983 | 30,97 | -1.269.132,86 | -98,5% | |
| 2025-10-09 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -33.842 | 31,92 | -1.080.172,34 | -83,8% | |
| 2025-10-09 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -15.042 | 32,41 | -487.439,02 | -37,8% | |
| 2025-10-08 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -14.336 | 34,34 | -492.285,34 | -38,2% | |
| 2025-10-08 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -60.926 | 33,75 | -2.056.471,83 | -159,6% | |
| 2025-10-07 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -27.624 | 33,84 | -934.710,53 | -72,5% | |
| 2025-10-06 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -18.156 | 37,77 | -685.830,19 | -53,2% | |
| 2025-10-06 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -34.847 | 37,12 | -1.293.565,94 | -100,4% | |
| 2025-10-06 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -17.760 | 36,00 | -639.391,97 | -49,6% | |
| 2025-10-03 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -4.701 | 38,14 | -179.316,82 | -13,9% | |
| 2025-10-03 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -3.200 | 37,37 | -119.593,92 | -9,3% | |
| 2025-10-02 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -5.300 | 42,32 | -224.290,70 | -17,4% | |
| 2025-10-02 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -13.001 | 40,13 | -521.706,73 | -40,5% | |
| 2025-10-02 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -7.700 | 39,57 | -304.710,56 | -23,6% | |
| 2025-10-02 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -4.937 | 37,21 | -183.684,54 | -14,3% | |
| 2025-10-02 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -1.513 | 38,38 | -58.064,55 | -4,5% | |
| 2025-10-01 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -1.400 | 39,19 | -54.869,50 | -4,3% | |
| 2025-09-16 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -447.278 | 1,54 | -688.852,85 | -53,5% | |
| 2025-09-15 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -400.000 | 1,64 | -656.320,00 | -50,9% | |
| 2025-09-12 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -300.000 | 1,75 | -526.230,00 | -40,8% | |
| 2025-09-11 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -284.805 | 1,83 | -521.420,99 | -40,5% | |
| 2025-09-10 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -350.000 | 1,82 | -635.285,00 | -49,3% | |
| 2025-09-09 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -449.226 | 2,00 | -898.631,69 | -69,7% | |
| 2025-09-08 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -464.421 | 1,99 | -924.058,46 | -71,7% | |
| 2025-09-05 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -400.000 | 1,97 | -787.280,00 | -61,1% | |
| 2025-09-04 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -453.016 | 1,93 | -873.641,36 | -67,8% | |
| 2025-09-03 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -554.612 | 2,00 | -1.107.061,01 | -85,9% | |
| 2025-08-28 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -806.351 | 2,01 | -1.621.975,04 | -125,9% | |
| 2025-08-27 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -611.647 | 2,01 | -1.226.535,73 | -95,2% | |
| 2025-08-26 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -284.190 | 2,08 | -591.342,55 | -45,9% | |
| 2025-08-25 | Reprogrammed Interchange LLC | 10% Owner | Open Market Sale | -387.346 | 2,12 | -819.740,34 | -63,6% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 5.673.078 | 0 | 5.673.078 | 96.499.052 | Neu | +100,0% | |
| RA CAPITAL MANAGEMENT, L.P. | 5.404.998 | 0 | 5.404.998 | 96.425.164 | Neu | +100,0% | |
| FCPM III SERVICES B.V. | 4.117.354 | 0 | 4.117.354 | 73.453.595 | Neu | +100,0% | |
| Venrock Adviser, LLC | 3.041.719 | 0 | 3.041.719 | 54.264.267 | Neu | +100,0% | |
| Frazier Life Sciences Management, L.P. | 2.543.939 | 0 | 2.543.939 | 45.383.872 | Neu | +100,0% | |
| Caligan Partners LP | 1.925.066 | 0 | 1.925.066 | 34.343.177 | Neu | +100,0% | |
| GREAT POINT PARTNERS LLC | 1.750.000 | 0 | 1.750.000 | 31.220.000 | Neu | +100,0% | |
| Paradigm Biocapital Advisors LP | 1.750.000 | 0 | 1.750.000 | 31.220.000 | Neu | +100,0% | |
| FMR LLC | 1.539.670 | 0 | 1.539.670 | 27.467.713 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.433.280 | 0 | 1.433.280 | 25.569.715 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 1.153.276 | 0 | 1.153.276 | 20.574.444 | Neu | +100,0% | |
| STATE STREET CORP | 1.118.458 | 0 | 1.118.458 | 19.953.291 | Neu | +100,0% | |
| NEXTBio Capital Management LP | 999.967 | 0 | 999.967 | 17.839.411 | Neu | +100,0% | |
| BlackRock, Inc. | 794.759 | 0 | 794.759 | 14.178.501 | Neu | +100,0% | |
| Logos Global Management LP | 750.000 | 0 | 750.000 | 13.380.000 | Neu | +100,0% | |
| Rosalind Advisors, Inc. | 700.000 | 0 | 700.000 | 12.488.000 | Neu | +100,0% | |
| NAN FUNG TRINITY (HK) Ltd | 646.550 | 0 | 646.550 | 11.902.986 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 555.702 | 0 | 555.702 | 9.913.724 | Neu | +100,0% | |
| UBS Group AG | 488.368 | 0 | 488.368 | 8.712.485 | Neu | +100,0% | |
| BRAIDWELL LP | 466.774 | 0 | 466.774 | 8.327.248 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 408.808 | 0 | 408.808 | 7.293.135 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 342.573 | 0 | 342.573 | 6.114.830 | Neu | +100,0% | |
| Clearline Capital LP | 326.168 | 0 | 326.168 | 5.818.837 | Neu | +100,0% | |
| SPHERA FUNDS MANAGEMENT LTD. | 321.917 | 0 | 321.917 | 5.742.999 | Neu | +100,0% | |
| Laurion Capital Management LP | 318.670 | 0 | 318.670 | 5.685.073 | Neu | +100,0% | |
| Propel Bio Management, LLC | 314.543 | 0 | 314.543 | 5.587.368 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 261.891 | 0 | 261.891 | 4.672.135 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 258.587 | 0 | 258.587 | 4.613.192 | Neu | +100,0% | |
| Jump Financial, LLC | 173.028 | 0 | 173.028 | 3.086.820 | Neu | +100,0% | |
| TUDOR INVESTMENT CORP ET AL | 152.571 | 0 | 152.571 | 2.721.867 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 148.768 | 0 | 148.768 | 2.654.021 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 128.839 | 0 | 128.839 | 2.298.488 | Neu | +100,0% | |
| MORGAN STANLEY | 116.721 | 0 | 116.721 | 2.082.303 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 112.892 | 0 | 112.892 | 2.013.993 | Neu | +100,0% | |
| AXIOM INVESTORS LLC /DE | 95.745 | 0 | 95.745 | 1.708.091 | Neu | +100,0% | |
| Quadrature Capital Ltd | 76.630 | 0 | 76.630 | 1.367.079 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 75.890 | 0 | 75.890 | 1.353.877 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 75.465 | 0 | 75.465 | 1.346.296 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 64.549 | 0 | 64.549 | 1.151.554 | Neu | +100,0% | |
| ALPS ADVISORS INC | 54.998 | 0 | 54.998 | 1.012.513 | Neu | +100,0% | |
| JOHNSON & JOHNSON | 53.732 | 0 | 53.732 | 958.579 | Neu | +100,0% | |
| Simplify Asset Management Inc. | 53.510 | 0 | 53.510 | 954.618 | Neu | +100,0% | |
| Rafferty Asset Management, LLC | 50.505 | 0 | 50.505 | 901.009 | Neu | +100,0% | |
| Brevan Howard Capital Management LP | 42.217 | 0 | 42.217 | 753.151 | Neu | +100,0% | |
| Irenic Capital Management LP | 32.663 | 0 | 32.663 | 582.708 | Neu | +100,0% | |
| Engineers Gate Manager LP | 26.880 | 0 | 26.880 | 479.539 | Neu | +100,0% | |
| Squarepoint Ops LLC | 25.482 | 0 | 25.482 | 454.599 | Neu | +100,0% | |
| Sarissa Capital Management LP | 25.399 | 0 | 25.399 | 453.118 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 22.216 | 0 | 22.216 | 396.333 | Neu | +100,0% | |
| PROFUND ADVISORS LLC | 22.015 | 0 | 22.015 | 392.748 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 2951 von typischerweise 8401 Fonds (35 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| NAN FUNG TRINITY (HK) Ltd | 646.550 | 0 | +100,0% | 11.902.986 | 85,45 | 100 % | 1 Q |
| ALPS ADVISORS INC | 54.998 | 0 | +100,0% | 1.012.513 | 7,27 | 100 % | 1 Q |
| Y-Intercept (Hong Kong) Ltd | 17.238 | 0 | +100,0% | 317.352 | 2,28 | 100 % | 2 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 14.300 | 0 | +100,0% | 263.263 | 1,89 | 100 % | 7 Q |
| Police & Firemen's Retirement System of New Jersey | 12.035 | 0 | +100,0% | 221.564 | 1,59 | 100 % | 1 Q |
| China Universal Asset Management Co., Ltd. | 8.624 | 7.368 | +17,0% | 158.768 | 1,14 | 100 % | 4 Q |
| Mirae Asset Global Investments Co., Ltd. | 2.423 | 2.166 | +11,9% | 44.607 | 0,32 | 100 % | 4 Q |
| Sterling Capital Management LLC | 355 | 0 | +100,0% | 6.536 | 0,05 | 0 % | 1 Q |
| SIGNATUREFD, LLC | 147 | 39 | +276,9% | 2.706 | 0,02 | 0 % | 2 Q |
| SBI Securities Co., Ltd. | 3 | 3 | 0,0% | 55 | 0,00 | 100 % | 7 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 10 | 0,8 | 14 |
| 31.03.2026 | ✓ | 80 | 41,9 | 742 |
| 31.12.2025 | ✓ | 55 | 26,1 | 339 |
| 30.09.2025 | ✓ | 38 | 3,8 | 186 |
| 30.06.2025 | ✓ | 35 | 57,1 | 91 |
| 31.03.2025 | ✓ | 46 | 60,6 | 43 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| TCG Crossover Management, LLC | 5.673.078 | 96.499.052 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.433.280 | 25.569.715 |
| MARSHALL WACE, LLP | 1.153.276 | 20.574.444 |
| Rosalind Advisors, Inc. | 700.000 | 12.488.000 |
| BOOTHBAY FUND MANAGEMENT, LLC | 555.702 | 9.913.724 |
| BRAIDWELL LP | 466.774 | 8.327.248 |
| Clearline Capital LP | 326.168 | 5.818.837 |
| Propel Bio Management, LLC | 314.543 | 5.587.368 |
| Jump Financial, LLC | 173.028 | 3.086.820 |
| RENAISSANCE TECHNOLOGIES LLC | 128.839 | 2.298.488 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| Venrock Adviser, LLC | 3.041.719 | 1.097.953 | +56.5 % | 54.264.267 |
| STATE STREET CORP | 1.118.458 | 1.027.405 | +1128.4 % | 19.953.291 |
| Caligan Partners LP | 1.925.066 | 999.999 | +108.1 % | 34.343.177 |
| Logos Global Management LP | 750.000 | 650.000 | +650.0 % | 13.380.000 |
| FCPM III SERVICES B.V. | 4.117.354 | 500.000 | +13.8 % | 73.453.595 |
| GREAT POINT PARTNERS LLC | 1.750.000 | 379.893 | +27.7 % | 31.220.000 |
| BlackRock, Inc. | 794.759 | 329.123 | +70.7 % | 14.178.501 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 232.608 | 217.789 | +1469.7 % | 4.149.727 |
| UBS Group AG | 488.368 | 196.250 | +67.2 % | 8.712.485 |
| GEODE CAPITAL MANAGEMENT, LLC | 342.573 | 156.765 | +84.4 % | 6.114.830 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 1.539.670 | -986.500 | -39.1 % | 27.467.713 |
| CITADEL ADVISORS LLC | 148.768 | -285.126 | -65.7 % | 2.654.021 |
| SPHERA FUNDS MANAGEMENT LTD. | 321.917 | -88.500 | -21.6 % | 5.742.999 |
| JANE STREET GROUP, LLC | 75.890 | -15.920 | -17.3 % | 1.353.877 |
| TUDOR INVESTMENT CORP ET AL | 152.571 | -15.102 | -9.0 % | 2.721.867 |
| INDEPENDENT FINANCIAL GROUP, LLC | 13.975 | -3.025 | -17.8 % | 249.314 |
| Engineers Gate Manager LP | 26.880 | -1.324 | -4.7 % | 479.539 |
| BARCLAYS PLC | 136 | -1.263 | -90.3 % | 2.426 |
| CITIGROUP INC | 5.373 | -967 | -15.3 % | 95.854 |
Zusätzlich aktuell von 32 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck | Δ-Balken |
|---|---|---|---|---|---|---|---|
| 21.07.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 19,90 % | 12.937.855 | 0,00 pp | Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6… | |
| 21.07.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,90 % | 12.931.166 | 0,00 pp | Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6… | |
| 15.05.2026 | Verve Capital Limited | Passiv (13G/A) | 9,30 % | 4.999.272 | -0,60 pp | – | |
| 15.05.2026 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 9,90 % | 5.083.877 | 0,00 pp | – | |
| 06.05.2026 | Qiming Venture Partners VIII-HC, L.P. (+1) | Passiv (13G/A) | 2,00 % | 1.089.767 | -0,80 pp | – | |
| 06.05.2026 | Qiming Venture Partners VIII Investments, LLC (+1) | Passiv (13G/A) | 1,70 % | 910.172 | -0,70 pp | – | |
| 06.05.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 3,20 % | 1.539.670 | -3,30 pp | – | |
| 22.04.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 19,90 % | 12.896.519 | 0,00 pp | – | |
| 22.04.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,90 % | 12.889.830 | 0,00 pp | – | |
| 15.04.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,90 % | 12.732.418 | 0,00 pp | – | |
| 15.04.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 19,90 % | 12.739.024 | 0,00 pp | – | |
| 11.04.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,90 % | 12.548.036 | 0,00 pp | – | |
| 11.04.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 19,90 % | 12.554.642 | 0,00 pp | – | |
| 08.04.2026 | RA Capital Healthcare Fund, L.P. (+3) | Aktivist (13D/A) | 19,90 % | 12.399.706 | 0,00 pp | – | |
| 01.04.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,90 % | 12.180.918 | 0,00 pp | – | |
| 01.04.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 19,90 % | 12.187.524 | 0,00 pp | – | |
| 01.04.2026 | Chen Yu | Passiv (13G) | 10,50 % | 5.673.078 | Neu | – | |
| 01.04.2026 | TCG Crossover Fund III, L.P. (+3) | Passiv (13G) | 5,20 % | 2.836.539 | Neu | – | |
| 16.03.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 19,90 % | 9.023.068 | +5,90 pp | Item 4 of the Statement is amended and supplemented as follows: On March 12, 2026, the … | |
| 16.03.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,90 % | 9.016.295 | +5,90 pp | Item 4 of the Statement is amended and supplemented as follows: On March 12, 2026, the … | |
| 17.02.2026 | Verve Capital Limited | Passiv (13G/A) | 9,90 % | 4.297.464 | 0,00 pp | – | |
| 17.02.2026 | Venrock Healthcare Capital Partners III, L.P. (+6) | Passiv (13G/A) | 9,90 % | 2.216.075 | 0,00 pp | – | |
| 17.02.2026 | Great Point Partners, LLC (+2) | Passiv (13G/A) | 3,30 % | 1.370.107 | -2,33 pp | – | |
| 17.02.2026 | Paradigm BioCapital International Fund Ltd. | Passiv (13G/A) | 4,00 % | 1.546.061 | -3,60 pp | – | |
| 17.02.2026 | Paradigm BioCapital Advisors GP LLC (+2) | Passiv (13G/A) | 4,50 % | 1.750.000 | -4,10 pp | – | |
| 13.02.2026 | Qiming Venture Partners VIII Investments, LLC (+1) | Passiv (13G/A) | 2,40 % | 910.172 | -2,15 pp | – | |
| 13.02.2026 | Qiming Venture Partners VIII-HC, L.P. (+1) | Passiv (13G/A) | 2,80 % | 1.089.767 | -2,64 pp | – | |
| 05.02.2026 | Abigail P. Johnson (+1) | Passiv (13G/A) | 6,50 % | 2.526.170 | -5,00 pp | – | |
| 23.12.2025 | Forbion Growth Opportunities Fund III Cooperatief U.A. (+2) | Aktivist (13D) | 9,99 % | 10.237.714 | 0,00 pp | The Reporting Persons acquired their shares of Common Stock as an investment in the ordi… | |
| 19.12.2025 | Frazier Life Sciences XI, L.P. (+2) | Passiv (13G) | 0,10 % | 21.114 | Neu | – | |
| 19.12.2025 | Frazier Life Sciences XII, L.P. (+2) | Passiv (13G) | 0,70 % | 264.824 | Neu | – | |
| 19.12.2025 | Frazier Life Sciences Public Fund, L.P. (+2) | Passiv (13G) | 5,80 % | 2.258.001 | Neu | – | |
| 18.12.2025 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 14,00 % | 5.411.521 | +4,10 pp | Item 4 of the Statement is amended and supplemented as follows: On December 18, 2025 Dr… | |
| 18.12.2025 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 14,00 % | 5.404.998 | +4,10 pp | Item 4 of the Statement is amended and supplemented as follows: On December 18, 2025 Dr… | |
| 17.12.2025 | Great Point Partners, LLC (+2) | Passiv (13G) | 5,63 % | 1.234.486 | Neu | – | |
| 18.11.2025 | Paradigm BioCapital International Fund Ltd. | Passiv (13G) | 7,60 % | 1.546.061 | +7,60 pp | – | |
| 18.11.2025 | Paradigm BioCapital Advisors GP LLC (+2) | Passiv (13G) | 8,60 % | 1.750.000 | -0,90 pp | – | |
| 14.11.2025 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 9,90 % | 2.338.754 | -1,50 pp | – | |
| 14.11.2025 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 9,90 % | 2.345.277 | -1,60 pp | – | |
| 07.11.2025 | Abigail P. Johnson (+1) | Passiv (13G) | 11,50 % | 788.447 | +9,80 pp | – |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -219.585.000 $ | -5,11 $ | 506.746.000 $ | -150.424.000 $ |
| 2025-12-31 | 10-K | – | -695.981.000 $ | -70,50 $ | 464.126.000 $ | -164.312.000 $ |
| 2025-09-30 | 10-Q | – | -812.684.000 $ | -121,63 $ | 176.237.000 $ | -2.225.487.000 $ |
| 2025-06-30 | 10-Q | – | -1.573.669.000 $ | -12,56 $ | 205.371.000 $ | -1.505.700.000 $ |
| 2025-03-31 | 10-Q | – | -32.486.000 $ | -5,21 $ | 109.312.000 $ | 66.069.000 $ |
| 2024-12-31 | 10-K | – | -116.914.000 $ | -34,03 $ | 142.891.000 $ | 96.664.000 $ |
| 2024-09-30 | 10-Q | – | -27.559.000 $ | -8,05 $ | 115.991.000 $ | 72.955.000 $ |
| 2024-06-30 | 10-Q | – | -27.839.000 $ | -0,41 $ | 141.588.000 $ | 98.080.000 $ |
| 2024-03-31 | 10-Q | – | -30.804.000 $ | -0,45 $ | 167.030.000 $ | 123.035.000 $ |
| 2023-12-31 | 10-K | – | -117.863.000 $ | -1,75 $ | 198.126.000 $ | 150.724.000 $ |
| 2023-09-30 | 10-Q | – | -33.190.000 $ | -0,49 $ | 223.023.000 $ | 174.781.000 $ |
| 2023-06-30 | 10-Q | – | -29.979.000 $ | -0,45 $ | 250.986.000 $ | 204.450.000 $ |
| 2023-03-31 | 10-Q | – | -28.433.000 $ | -0,43 $ | 277.533.000 $ | 230.215.000 $ |
| 2022-12-31 | 10-K | – | -92.094.000 $ | -2,33 $ | 299.366.000 $ | 250.607.000 $ |
| 2022-09-30 | 10-Q | – | -23.788.000 $ | -0,63 $ | 206.373.000 $ | 158.734.000 $ |
| 2022-06-30 | 10-Q | – | -21.659.000 $ | -0,58 $ | 224.615.000 $ | 174.974.000 $ |
| 2022-03-31 | 10-Q | – | -22.737.000 $ | -0,61 $ | 234.269.000 $ | 194.447.000 $ |
| 2021-12-31 | 10-K | – | -68.899.000 $ | -2,10 $ | 242.590.000 $ | 216.263.000 $ |
| 2021-09-30 | 10-Q | – | -18.554.000 $ | -0,50 $ | 258.632.000 $ | 232.957.000 $ |
| 2021-06-30 | 10-Q | – | -18.370.000 $ | -0,50 $ | 275.143.000 $ | 250.108.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 13.05.2026 | – | -5,11 |
| Q3 2025 | 30.09.2025 | 13.11.2025 | – | -121,63 |
| Q2 2025 | 30.06.2025 | 12.08.2025 | – | -12,56 |
| Q1 2025 | 31.03.2025 | 14.05.2025 | – | -5,21 |
| Q3 2024 | 30.09.2024 | 07.11.2024 | – | -8,05 |
| Q2 2024 | 30.06.2024 | 08.08.2024 | – | -0,41 |
| Q1 2024 | 31.03.2024 | 09.05.2024 | – | -0,45 |
| Q3 2023 | 30.09.2023 | 07.11.2023 | – | -0,49 |
| Q2 2023 | 30.06.2023 | 10.08.2023 | – | -0,45 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 13.05.2026 | 10-Q | 31.03.2026 | 43 Tage | SEC » |
| 30.03.2026 | 10-K | 31.12.2025 | 89 Tage | SEC » |
| 13.11.2025 | 10-Q | 30.09.2025 | 44 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 14.05.2025 | 10-Q | 31.03.2025 | 44 Tage | SEC » |
| 20.03.2025 | 10-K | 31.12.2024 | 79 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 08.08.2024 | 10-Q/A | 31.03.2024 | 130 Tage | SEC » |
| 08.08.2024 | 10-Q | 30.06.2024 | 39 Tage | SEC » |
| 09.05.2024 | 10-Q | 31.03.2024 | 39 Tage | SEC » |
| 20.03.2024 | 10-K | 31.12.2023 | 80 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 10.08.2023 | 10-Q | 30.06.2023 | 41 Tage | SEC » |
| 11.05.2023 | 10-Q | 31.03.2023 | 41 Tage | SEC » |
| 23.03.2023 | 10-K | 31.12.2022 | 82 Tage | SEC » |
| 10.11.2022 | 10-Q | 30.09.2022 | 41 Tage | SEC » |
| 11.08.2022 | 10-Q | 30.06.2022 | 42 Tage | SEC » |
| 12.05.2022 | 10-Q | 31.03.2022 | 42 Tage | SEC » |
| 14.03.2022 | 10-K | 31.12.2021 | 73 Tage | SEC » |
| 10.11.2021 | 10-Q | 30.09.2021 | 41 Tage | SEC » |
| 09.08.2021 | 10-Q | 30.06.2021 | 40 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 25.03.2021 | 10-K | 31.12.2020 | 84 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 12.11.2025 | Kapitalerhöhung | $100,0 Mio · $10,00/Aktie | SEC » |
| 10.11.2025 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 27.08.2025 | Kapitalerhöhung | $119,7 Mio | SEC » |
| 23.12.2022 | Kapitalerhöhung | $125,0 Mio | SEC » |
| 08.12.2022 | Kapitalerhöhung | $61,9 Mio · $4,30/Aktie | SEC » |
| 08.02.2021 | Börsengang | $164,5 Mio · $18,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 27.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2026 | HV-Einladung | 11.06.2026 Jahres-HV | 15.04.2026 | DEF 14A | SEC » |
| 08.08.2025 | HV-Einladung | 25.08.2025 a.o. HV | 28.07.2025 | DEF 14A | SEC » |
| 29.07.2025 | Vorläufig | — | — | PRE 14A | SEC » |
| 30.04.2025 | HV-Einladung | — | — | DEFR14A | SEC » |
| 08.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 08.04.2025 | HV-Einladung | 22.05.2025 Jahres-HV | 24.03.2025 | DEF 14A | SEC » |
| 28.03.2025 | Vorläufig | — | — | PRE 14A | SEC » |
| 02.05.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 09.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 09.04.2024 | HV-Einladung | 23.05.2024 Jahres-HV | 26.03.2024 | DEF 14A | SEC » |
| 14.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 14.04.2023 | HV-Einladung | 26.05.2023 Jahres-HV | 03.04.2023 | DEF 14A | SEC » |
| 28.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2022 | HV-Einladung | 14.06.2022 Jahres-HV | 18.04.2022 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (07.07.2026)
HOCH Abgang Schlüsselpersonen (07.07.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 07.07.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | general solicitation or general advertising. Item 5.02 Departure of Directors or Certain Officers; Election of… |
| 09.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 03.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 14.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 07.07.2026 | Personalwechsel | -0,10 | 50 | Andrew Levin, M.D., Ph.D., hat seine Tätigkeit als Mitglied des Vor Biopharma Inc.-Gremiums nacheinander beendet. | SEC |
| 12.06.2026 | HV-Abstimmung | 0,05 | 25 | Vor Biopharma hielt die Jahresaktionärsversammlung ab. Mit einer Beteiligung von 62,77% (34,0 Mio. Aktien) stimmten die Aktionäre über drei … 🔒 | SEC |
| 08.06.2026 | Guidance-Update | 0,70 | 75 | Vor Biopharmas Partner RemeGen erhielt von der chinesischen Zulassungsbehörde (NMPA) bedingte Zulassung für telitacicept bei IgA-Nephropathi… 🔒 | SEC |
| 27.03.2026 | Wesentliche Vereinbarung | 0,50 | 70 | Vor Biopharma hat einen Securities Purchase Agreement mit TCGX-Investoren für einen Private Placement unterzeichnet und wird 5,338,078 Stamm… 🔒 | SEC |
| 12.01.2026 | Sonstiges | 0,15 | 30 | Vor Biopharma gibt vorläufige Finanzinformationen für 2025 bekannt (Liquidität: ~$450 Mio.) und wird auf der JP Morgan Healthcare Conference… 🔒 | SEC |